Interactions between genetic predisposition and environmental toxicants for development of lung cancer

El‐Zein, Randa; Conforti-Froes, Nívea; Au, William W.

doi:10.1002/(sici)1098-2280(1997)30:2<196::aid-em12>3.0.co;2-8

Cited by 45 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, IORs for case-control and case-only for GSTT1-smoking were more than one indicating more than multiplicative effect in smokers with susceptibility genotype (IOR cc : 2.47; 95% CI: 0.27-22.30 and IOR co : 2.00; 95% CI: 0.34-11.74, respectively). Similarly, more than a multiplicative interaction effect between GSTM1-alcohol and CYP1A1-alcohol in both designs were observedDiscussionMany reports have been written about gene-environment interaction and its association with cancer susceptibility, especially the relationship between polymorphic chemical metabolizing genes and environmental carcinogens[14,16,17,40,41]. ChemicalTable 1.…”

mentioning

confidence: 99%

Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: Exploring some gene?gene and gene?environment interactions

Cáceres

Iturrieta

Acevedo³

et al. 2005

Eur J Epidemiol

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: Exploring some gene?gene and gene?environment interactions

Cáceres

Iturrieta

Acevedo³

et al. 2005

Eur J Epidemiol

View full text Add to dashboard Cite

show abstract

“…Los homocigotos para alelo GSTM1*0, presentaron una frecuencia de 51.43% del total de la población en estudio. En términos generales se estima que las frecuencias varían entre CUADRO 1 Distribución por sexo y edad de la población de estudio (N=140) un 30 a 70%, en diferentes poblaciones (El-Zein et al 1997, Setiawan et al 2000. Los individuos con el genotipo homocigota para el alelo nulo del gen GSTM1, no presentaron diferencia en el riesgo de padecer de cáncer gástrico o lesiones precancerosas con respecto a los individuos que poseían el alelo normal.…”

Section: Discussionunclassified

Polimorfismos en los genes de desintoxicación CYP1A1, CYP2E1, GSTT1 y GSTM1 en la susceptibilidad al cáncer gástrico

González

Ramírez

Cuenca

et al. 2014

RBT

View full text Add to dashboard Cite

Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility. Cytochrome P450 (CYP) and glutathione S-transferase (GST) enzymes are involved in activation and detoxification of many potential carcinogens. Genetic polymorphisms in those enzymes have been found to influence the interindividual susceptibility to cancer. Some polymorphisms of those enzymes have been associated specifically with susceptibility to gastric cancer. We conducted a study in a Costa Rican population, where gastric cancer incidence and mortality rates are among the highest in the world. We investigated whether such variations affected the risk of developing gastric cancer. Subjects included 31 with gastric cancer, 58 controls with gastric injures others than cancer and 51 normal controls confirmed by X-rays (double-contrast) or endoscopic diagnostic. DNA from peripheral white blood cell was obtained from all subjects. Deletion of GSTT1 and GSTM1 was assessed by multiplex PCR and genotyping of CYP2E1 was performed using a PCRbased restriction fragment length polymorphism assay with the restriction enzyme PstI and the gene CYP1A1 using the restriction enzyme MspI. The prevalence of CYP1A1 MspI polymorphism, GSTT1 and GSTM1 null genotype was similar in the three groups of individuals (p=0.73, p=0.88 y p= 0.89 respectively). Our findings suggest that the polymorphism CYP2E1 PstI could be associated with a reduced risk of having gastric cancer (OR=0.09, IC 95% :0.01-0.83). Rev. Biol. Trop. 52(3): 591-600. Epub 2004 Dic 15.

show abstract

“…Cyctochrome p450 genes, in part, determine how quickly environmental toxins and toxicants are metabolized the body; as a result, individuals with extensive-metabolizing variants may be at increased risk for cancers related to environmental toxicants that are metabolized into more reactive forms by CYP2D6. Two recent studies have implicated extensive-metabolizing CYP2D6 variants with cancer in different populations; individuals with this CYP2D6 variant had a greater risk for lung cancer among North Indians and American smokers [el-Zein et al, 1997;Sobti et al, 2003]. Additionally, a recent study has shown the short allele of the serotonin transporter promoter polymorphism (SERTPR) to be associated with increased development of depression following stressful life events [Caspi et al, 2003], and a meta-analysis concluded that the same mutation was associated with suicidal behavior [Anguelova et al, 2003].…”

Section: Ethical and Practical Considerationsmentioning

confidence: 99%

Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils

Rasmussen‐Torvik

McAlpine

2007

Depress. Anxiety

View full text Add to dashboard Cite

This article examines evidence for the potential benefit of genetic testing for SSRI response, as well as potential ethical and practical implications of the implementation of this test into standard psychiatric practice. We reviewed three areas of the literature: the burden of treatment-resistant and treatment-intolerant major depressive disorders, the evidence for the value of genetic testing to predict drug response, and the ethical and practical issues of genetic testing in usual care. Treatment resistance and treatment intolerance are common for persons treated with selective serotonin reuptake inhibitors (SSRIs) and are associated with both financial and quality-of-life costs. There is strong evidence from association studies that some polymorphisms are associated with SSRI response. However, no randomized trials have yet tested the efficacy of genetic tests to improve outcome in those with treatment resistance or treatment intolerance to SSRIs. Given the nonspecific nature of the test proposed, several ethical concerns are also involved with administering the genetic tests to patients. A randomized trial comparing response in those treated with standard psychiatric care and in those treated with psychiatric care tailored as a result of genetic test results should be completed before the implementation of these tests can be considered. Additionally, the ethical and practical questions concerning the tests must be addressed now, so that the potential impact of these tests on patient care can be well understood prior to adoption in standard practice.

show abstract

Interactions between genetic predisposition and environmental toxicants for development of lung cancer

Cited by 45 publications

References 50 publications

Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: Exploring some gene?gene and gene?environment interactions

Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: Exploring some gene?gene and gene?environment interactions

Polimorfismos en los genes de desintoxicación CYP1A1, CYP2E1, GSTT1 y GSTM1 en la susceptibilidad al cáncer gástrico

Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils

Contact Info

Product

Resources

About